MannKind Corp (MNKD):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:MannKind Corp (MNKD) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7269
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. It has manufacturing facility in Danbury, Connecticut and sells its product through wholesale distributors and specialty pharmacies. MannKind is headquartered in California, the US.

MannKind Corp (MNKD) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MannKind Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
MannKind Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
MannKind Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
MannKind Corp, Medical Equipment, Deal Details 11
Partnerships 11
MannKind and One Drop to Enter into Agreement 11
United Therapeutics to Enter into Licensing Agreement with MannKind 12
Equity Offering 13
MannKind Raises USD28 Million in Private Placement of Shares 13
Mannkind to Raise USD61 Million in Private Placement of Shares 15
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 17
MannKind Raises USD36.2 Million in Private Placement of Shares 18
Mannkind Raises USD50 Million in Private Placment of Shares 19
MannKind Announces Public Offering Of Common Stock For US$50 Million 21
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 22
MannKind Completes Public Offering Of Units For US$86 Million 23
Debt Offering 25
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 25
MannKind Corp – Key Competitors 27
MannKind Corp – Key Employees 28
MannKind Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Strategy And Business Planning 30
Sep 05, 2017: MannKind Relocates Headquarters to Westlake Village 30
Financial Announcements 31
Aug 02, 2018: MannKind Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET 31
May 09, 2018: MannKind Reports 2018 First Quarter Financial Results 33
Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results 34
Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 36
May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 38
Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 39
Corporate Communications 40
Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer 40
Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 41
Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 42
Jun 28, 2017: Mannkind draws remaining funds under mann group loan arrangement 43
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 44
Legal and Regulatory 45
Jun 25, 2018: MannKind Set to Join Russell 3000 Index 45
Other Significant Developments 46
Jan 03, 2017: MannKind Receives $1 Million Milestone From RLS 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
MannKind Corp, Medical Equipment, Key Facts, 2017 2
MannKind Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
MannKind Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
MannKind Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Deals By Market, 2012 to YTD 2018 9
MannKind Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
MannKind and One Drop to Enter into Agreement 11
United Therapeutics to Enter into Licensing Agreement with MannKind 12
MannKind Raises USD28 Million in Private Placement of Shares 13
Mannkind to Raise USD61 Million in Private Placement of Shares 15
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 17
MannKind Raises USD36.2 Million in Private Placement of Shares 18
Mannkind Raises USD50 Million in Private Placment of Shares 19
MannKind Announces Public Offering Of Common Stock For US$50 Million 21
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 22
MannKind Completes Public Offering Of Units For US$86 Million 23
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 25
MannKind Corp, Key Competitors 27
MannKind Corp, Key Employees 28
MannKind Corp, Other Locations 29
MannKind Corp, Subsidiaries 29

List of Figures
MannKind Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
MannKind Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
MannKind Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
MannKind Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
MannKind Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
MannKind Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[MannKind Corp (MNKD):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nakanishi Inc (7716):企業の財務・戦略的SWOT分析
    Nakanishi Inc (7716) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • VistaGen Therapeutics Inc (VTGN):製薬・医療:M&Aディール及び事業提携情報
    Summary VistaGen Therapeutics Inc (VistaGen) is a biopharmaceutical company that develops new generation medicines for neuropsychiatric disorders. The company’s product includes AV-101, which is a oral antidepressant which is currently under clinical study in National Institute of Mental Health (NIM …
  • Jotun AS:企業の戦略的SWOT分析
    Jotun AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Access Bio Inc (950130):医療機器:M&Aディール及び事業提携情報
    Summary Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic technology such as immunochemical, biochemical and molecular products. …
  • RP Management LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary RP Management LLC (RP Management) is a life sciences financing company that offers biopharmaceutical products. The company’s products include thalomid, myozyme, lexiscan, rituxan, atripla, lyrica, prezista, letairis, januvia, onglyza, neupogen, rotateq, cubicin, savella, and others. It also …
  • Pfenex Inc (PFNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company’s lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple scl …
  • QNB Finansbank (FINBN):企業の財務・戦略的SWOT分析
    QNB Finansbank (FINBN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Alnylam Pharmaceuticals Inc (ALNY):企業の財務・戦略的SWOT分析
    Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Hyundai Motor Co (005380)-エネルギー分野:企業M&A・提携分析
    Summary Hyundai Motor Company (Hyundai) is a global manufacturer of automobiles, which designs, develops and manufactures passenger and heavy duty automobiles and relevant parts. The company manufactures passenger cars under various brand names such as Centennial, Genesis, Veloster, Azera, Sonata, i …
  • SurModics Inc (SRDX):企業の財務・戦略的SWOT分析
    SurModics Inc (SRDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • AltaGas Ltd (ALA)-石油・ガス分野:企業M&A・提携分析
    Summary AltaGas Ltd. (AltaGas), is an energy utility. The company undertakes activities related to extraction, transmission, distribution and storage of natural gas. AltaGas generates electricity utilizing diverse fuel sources, such as wind, run-of-river hydro, geothermal and gas-fired generation pl …
  • OSRAM Opto Semiconductors GmbH:企業の戦略的SWOT分析
    OSRAM Opto Semiconductors GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Eastman Kodak Company:戦略・SWOT・企業財務分析
    Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report Summary Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Daybreak Oil and Gas Inc (DBRM):石油・ガス:M&Aディール及び事業提携情報
    Summary Daybreak Oil and Gas Inc (Daybreak) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include East Slopes project and Michigan Basin project. Its East Slopes project is located in south-eastern art of the San Joaquin Basin, California. Da …
  • Shoal Point Energy Ltd (SHP):石油・ガス:M&Aディール及び事業提携情報
    Summary Shoal Point Energy Ltd (Shoal Point Energy) is an oil and gas exploration and development company that acquires, develops, explores, and produces petroleum products. The company holds interests in Green Point Oil-in-Shale and Humber Arm Shale project. It also holds interests in the explorati …
  • National Thermal Power Corporation Ltd:企業の戦略・SWOT・財務分析
    National Thermal Power Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary National Thermal Power Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • MMC Corp Bhd (MMCCORP):企業の財務・戦略的SWOT分析
    Summary MMC Corp Bhd (MMC) is an investment holding company which carries out mining, mineral exploration and construction services. It operates through ports and logistics, energy and utilities, engineering and industrial development divisions. The company offers containers, bulk and breakbulk, liq …
  • DecImmune Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DecImmune Therapeutics Inc (DecImmune) is a pharmaceutical research company. The company develops a humanised antibody, which is used in preventing tissue damage and block inflammation caused from vascular injuries. It conducts research and development on N2, an innate IgM-mediated auto-immu …
  • Joslin Diabetes Center-製薬・医療分野:企業M&A・提携分析
    Summary Joslin Diabetes Center (Joslin) is a healthcare service provider that provides diabetes treatment, research and education services. The centers services include weight management programs, pregnancy program, eye care, diabetes prevention, research, diabetes patient education, adult diabetic …
  • Silver Fern Farms Limited:企業の戦略的SWOT分析
    Silver Fern Farms Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆